ArrowArtboardCreated with Sketch.Title ChevronCrossEye IconFacebook IconIcon FacebookGoogle Plus IconLayer 1InstagramCreated with Sketch.Linkedin IconIcon LinkedinShapeCreated with Sketch.Icon Mail ContactPath LayerIcon MailMenu BurgerIcon Opinion QuotePositive ArrowIcon PrintRSS IconIcon SearchSite TitleTitle ChevronTwitter IconIcon TwitterYoutube Icon
Health Technology

Hisamitsu Pharmaceutical Co., Inc.

  • 6,810.00 JPY
  • -70.00
  • -1.02%
  • Japan
    Oct 19, 2018
  • Ticker
    TKS(4530)
  • Prev. close
    6,880
  • Market cap (JPY)
    654,734M
  • Market cap (USD)
    5,820.12M
  • Shares
    95.16M

Business Summary

Hisamitsu Pharmaceutical Co., Inc. engages in the research, development, manufacture, and sale of pharmaceuticals and related products. Its products are sold under Salonpas, Salonsip, Mohrus, ByeBye-Fever, Lifecella, and Keplat brands. It also provides ethical pharmaceuticals, over the counter drugs, medical devices, health supplements, and topical analgesic products. The company was founded by Nihei Hisamitsu in 1847 and is headquartered in Tosu, Japan.

Financial Highlights

Feb 2018 JPYUSD
Revenue147,870M1,327.30M
Gross Profit92,182M827.44M
Operating income26,346M236.48M
Income before tax27,694M248.58M
Net income19,120M171.62M
EBITDA32,351M290.38M
Diluted EPS228.342.04
Dividends Per Share820.73
Total Assets299,913M2,810.67M
Total liabilities54,681M512.45M
Total equity244,000M2,286.67M
Operating cash flow30,453M273.35M
Currency in JPYCurrency in USD

Historical Data

 Feb 2014Feb 2015Feb 2016Feb 2017Feb 2018
Revenue 150,635M 156,743M 161,852M 145,925M 147,870M
Gross Profit 94,291M 98,734M 102,465M 91,840M 92,182M
Operating income 19,123M 20,527M 27,730M 26,306M 26,346M
Income before tax 33,727M 29,416M 27,922M 29,984M 27,694M
Net income 21,357M 18,784M 17,784M 20,395M 19,120M
EBITDA 26,615M 28,140M 36,275M 33,674M 32,351M
Diluted EPS 249.30 219.27 208.76 241.14 228.34
Dividends Per Share 70 80 81 81.50 82
Total Assets 251,852M 285,440M 284,954M 278,820M 299,913M
Total liabilities 55,544M 63,386M 58,859M 49,611M 54,681M
Total equity 195,443M 221,023M 225,095M 228,108M 244,000M
Operating cash flow 35,845M 23,232M 30,923M 19,910M 30,453M
 Feb 2014Feb 2015Feb 2016Feb 2017Feb 2018
Revenue 1,512.76M 1,446.77M 1,340.64M 1,347.79M 1,327.30M
Gross Profit 946.92M 911.33M 848.73M 848.25M 827.44M
Operating income 192.04M 189.46M 229.69M 242.96M 236.48M
Income before tax 338.70M 271.51M 231.28M 276.93M 248.58M
Net income 214.47M 173.38M 147.30M 188.37M 171.62M
EBITDA 267.28M 259.73M 300.47M 311.02M 290.38M
Diluted EPS 2.50 2.02 1.72 2.22 2.04
Dividends Per Share 0.70 0.73 0.67 0.75 0.73
Total Assets 2,467.56M 2,387.72M 2,524.50M 2,492.02M 2,810.67M
Total liabilities 544.20M 530.22M 521.45M 443.41M 512.45M
Total equity 1,914.88M 1,848.86M 1,994.19M 2,038.77M 2,286.67M
Operating cash flow 359.97M 214.43M 256.14M 183.89M 273.35M

Valuation Measures

Feb 2018
PER33.87
ROA6.60%
ROE8.09%
Operating margin17.81%
Profit margin12.93%

Key executives

  • Chairman & Chief Executive Officer: Hirotaka Nakatomi
  • President, COO & Representative Director: Kazuhide Nakatomi
  • Director, Manager-Finance & Investor Relations: Shinichiro Takao
  • Executive Officer, GM-Research & Development: Takaaki Terahara
  • Director, Manager-Legal Affairs & Head-Compliance: Nobuo Tsutsumi

Shareholders

  • Hisamitsu Pharmaceutical Co., Inc. (12.0%)
  • Government of Japan (5.3%)
  • Bank of Tokyo Mitsubishi UFJ Pension Fund (4.6%)
  • Nishi Nippon City Bank Pension Fund (4.5%)
  • Nippon Life Insurance Co. (4.1%)
  • Fukuoka Financial Group, Inc. (3.8%)
  • The Bank of Saga Ltd. (2.4%)
  • Hisamitsu Pharmaceutical Business Association (2.3%)
  • Sumitomo Mitsui Banking Pension Fund (2.1%)
  • Mitsubishi UFJ Financial Group, Inc. (1.9%)

Contact Details

Related Companies

  • Nakatomi Memorial Foundation
  • Hisamitsu Pharmaceutcal Co. Ltd.
  • Hisamitsu Farmaceutica do Brasil Ltda.
  • Hisamitsu Vietnam Pharmaceutical Co. Ltd.
  • PT Hisamitsu Pharma Indonesia
  • Hisamitsu UK Ltd.
  • Hisamitsu Pharmaceutical Business Association
  • Hisamitsu Pharmaceutical Tech Consulting (Beijing) Co. Ltd.
  • CRCC Media Co., Ltd.
  • Hisamitsu America, Inc.
  • Saga City Vision KK
  • Hisamitsu US, Inc.
  • SSP Co. Ltd. /Ethical Medicine Division/
  • Noven Pharmaceuticals, Inc.

Competitors

  • KemPharm, Inc.
  • DURECT Corporation
  • TherapeuticsMD, Inc.
  • Corium International, Inc.
Last Updated on 19 Oct, 2018

You have {{numberReadArticles}} FREE ARTICLE{{numberReadArticles-plural}} left this month

Subscribe to get unlimited access to all articles.

Get unlimited access
NAR site on phone, device, tablet

{{sentenceStarter}} {{numberReadArticles}} free article{{numberReadArticles-plural}} this month

Stay ahead with our exclusives on Asia; the most dynamic market in the world.

Benefit from in-depth journalism from trusted experts within Asia itself.

Try 3 months for $9

Offer ends September 30th

Your trial period has expired

You need a subscription to...

  • Read all stories with unlimited access
  • Use our mobile and tablet apps
See all offers and subscribe

Your full access to the Nikkei Asian Review has expired

You need a subscription to:

  • Read all stories with unlimited access
  • Use our mobile and tablet apps
See all offers
NAR on print phone, device, and tablet media